Background Lung cancer is the leading cause of cancer-related death worldwide, with non-
small cell lung cancer (NSCLC) accounting for most cases. While radiotherapy has …

Radiotherapy, along with other loco-regional interventions, is conventionally utilized as a
palliative approach to alleviate symptoms and mitigate oncological emergencies in …

BACKGROUND: The optimal treatment for non-small cell lung cancer (NSCLC) patients with
asymptomatic brain metastasis is still controversial. This study aimed to analyze the outcome …

Abstract Between 30% and 50% of patients with non–small-cell lung cancer (NSCLC) will
develop cerebral metastases in the course of their illness. As improvements are made in the …

Recent advances in systemic cytotoxic and molecularly targeted therapies coupled with
technologic strides in radiotherapy have the potential to improve outcomes for patients with …

Opinion statement Brain metastases are a common complication for patients with non-small
cell lung cancer and a significant cause of morbidity and mortality. In the past, treatment of …

Unless confirmation of a solitary brain metastasis is made in the context of absent
extracranial disease and good performance status, patients with metastatic brain disease …

Simple Summary Lung cancer is the most common primary malignancy that tends to
metastasize to the brain. Owing to improved survival of lung cancer patients, the prevalence …

Non-small cell lung cancer (NSCLC) with oncogenic driver mutations such as EGFR or ALK
has a high predilection for brain metastases (BMs) compared to unselected patients …

BACKGROUND. For patients with stage IV nonsmall cell lung cancer (NSCLC) who present
with brain metastasis (BMs), standard platinum‐based chemotherapy regimens have …